Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
First Sales Of Newly Approved Product Expected In Q1 2023
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
You may also be interested in...
The $3m gene therapy for the rare disease cerebral adrenoleukodystrophy marks bluebird’s second approval in just under a month.
The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.